MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597415 | Name: Spantide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Spantide antagonizes both bombesin & substance P; tachykinin receptor antagonist.

Chemical Structure

Spantide
Spantide
CAS#91224-37-2

Theoretical Analysis

MedKoo Cat#: 597415

Name: Spantide

CAS#: 91224-37-2

Chemical Formula: C75H108N20O13

Exact Mass: 1496.8405

Molecular Weight: 1497.81

Elemental Analysis: C, 60.14; H, 7.27; N, 18.70; O, 13.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Spantide; Spantide I; Substance P, arg(1)-trp(7,9)-leu(11)-; 1-Arg-7,9-trp-11-leu-substance P;
IUPAC/Chemical Name
(S)-2-((S)-1-(D-arginyl-L-prolyl-L-lysyl)pyrrolidine-2-carboxamido)-N1-((S)-5-amino-1-(((R)-1-(((S)-1-(((R)-1-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1,5-dioxopentan-2-yl)pentanediamide
InChi Key
SAPCBHPQLCZCDV-CHPWDEGWSA-N
InChi Code
InChI=1S/C75H108N20O13/c1-42(2)35-55(64(80)98)89-67(101)56(36-43(3)4)90-69(103)59(39-46-41-85-51-23-11-9-20-48(46)51)93-68(102)57(37-44-17-6-5-7-18-44)91-70(104)58(38-45-40-84-50-22-10-8-19-47(45)50)92-66(100)52(27-29-62(78)96)86-65(99)53(28-30-63(79)97)87-71(105)61-26-16-34-95(61)74(108)54(24-12-13-31-76)88-72(106)60-25-15-33-94(60)73(107)49(77)21-14-32-83-75(81)82/h5-11,17-20,22-23,40-43,49,52-61,84-85H,12-16,21,24-39,76-77H2,1-4H3,(H2,78,96)(H2,79,97)(H2,80,98)(H,86,99)(H,87,105)(H,88,106)(H,89,101)(H,90,103)(H,91,104)(H,92,100)(H,93,102)(H4,81,82,83)/t49-,52+,53+,54+,55+,56+,57+,58-,59-,60+,61+/m1/s1
SMILES Code
CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CC3=CC=CC=C3)NC([C@@H](CC4=CNC5=C4C=CC=C5)NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H]6N(C([C@H](CCCCN)NC([C@H]7N(C([C@@H](CCCNC(N)=N)N)=O)CCC7)=O)=O)CCC6)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,497.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tan-No K, Sakurada T, Yamada T, Sakurada S, Kisara K. Involvement of opioid receptors in the antinociception produced by intracerebroventricularly administered spantide in mice. Neuropeptides. 1995 Nov;29(5):293-9. PubMed PMID: 8587665. 2: Wiesenfeld-Hallin Z, Xu XJ, Kristensson K, Håkanson R, Feng DM, Folkers K. Antinociceptive and substance P antagonistic effects of intrathecally injected spantide II in rat: no signs of motor impairment or neurotoxicity. Regul Pept. 1990 Jun;29(1):1-11. PubMed PMID: 1697080. 3: Yanagisawa M, Otsuka M. Pharmacological profile of a tachykinin antagonist, spantide, as examined on rat spinal motoneurones. Br J Pharmacol. 1990 Aug;100(4):711-6. PubMed PMID: 1698496; PubMed Central PMCID: PMC1917608. 4: Beding-Barnekow B, Leander S, Ohlin M, Ninn-Pedersen K, Alkner U, Håkanson R. Systemic and intraocular uptake of spantide, a tachykinin antagonist, following topical application to the rabbit eye. Exp Eye Res. 1990 Jan;50(1):21-6. PubMed PMID: 1689665. 5: Folkers K, Feng DM, Asano N, Håkanson R, Weisenfeld-Hallin Z, Leander S. Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4833-5. PubMed PMID: 1693780; PubMed Central PMCID: PMC54212. 6: Pappas T, Hamel D, Debas H, Walsh J, Tache Y. Spantide: failure to antagonize bombesin-induced stimulation of gastrin secretion in dogs. Peptides. 1985 Sep-Oct;6(5):1001-3. PubMed PMID: 2417201. 7: Kikwai L, Babu RJ, Kanikkannan N, Singh M. Stability and degradation profiles of Spantide II in aqueous solutions. Eur J Pharm Sci. 2006 Feb;27(2-3):158-66. Epub 2005 Nov 2. PubMed PMID: 16266798. 8: Håkanson R, Leander S, Asano N, Feng DM, Folkers K. Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect. Regul Pept. 1990 Oct 29;31(1):75-82. PubMed PMID: 1702895. 9: Hazlett LD, McClellan SA, Barrett RP, Liu J, Zhang Y, Lighvani S. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807. PubMed PMID: 17251480. 10: Janecka A, Poels J, Fichna J, Studzian K, Vanden Broeck J. Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay. Regul Pept. 2005 Nov;131(1-3):23-8. PubMed PMID: 15990182. 11: Wiesenfeld-Hallin Z, Xu XJ, Håkanson R, Feng DM, Folkers K. The specific antagonistic effect of intrathecal spantide II on substance P- and C-fiber conditioning stimulation-induced facilitation of the nociceptive flexor reflex in rat. Brain Res. 1990 Sep 3;526(2):284-90. PubMed PMID: 1701683. 12: Maggi CA, Patacchini R, Feng DM, Folkers K. Activity of spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes. Eur J Pharmacol. 1991 Jun 18;199(1):127-9. PubMed PMID: 1716573. 13: Zubrzycka M, Janecka A, Traczyk WZ. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8. PubMed PMID: 10808247. 14: Togashi H, Yoshioka M, Minami M, Shimamura K, Saito H, Kitada C, Fujino M. Effect of the substance P antagonist spantide on adrenal sympathetic nerve activity in rats. Jpn J Pharmacol. 1987 Mar;43(3):253-61. PubMed PMID: 2438441. 15: Kikwai L, Babu RJ, Kanikkannan N, Singh M. Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J Pharm Pharmacol. 2004 Jan;56(1):19-25. PubMed PMID: 14979997. 16: Reid MS, Hökfelt T, Herrera-Marschitz M, Håkanson R, Feng DM, Folkers K, Goldstein M, Ungerstedt U. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity. Brain Res. 1990 Nov 5;532(1-2):175-81. PubMed PMID: 1704289. 17: Kincy-Cain T, Bost KL. Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II. J Immunol. 1996 Jul 1;157(1):255-64. PubMed PMID: 8683123. 18: Hoover DB. Effects of spantide on guinea pig coronary resistance vessels. Peptides. 1991 Sep-Oct;12(5):983-8. PubMed PMID: 1724800. 19: Post C, Freedman J, Paulsson I, Hökfelt T. Antinociceptive effects in mice after intrathecal injection of a substance P receptor antagonist, Spantide: lack of 'neurotoxic' action. Regul Pept. 1987 Sep;18(5-6):243-52. PubMed PMID: 2445004. 20: Sakurada T, Manome Y, Katsumata K, Uchiumi H, Tan-No K, Sakurada S, Kisara K. Naloxone-reversible effect of spantide on the spinally mediated behavioural response induced by neurokinin-2 and -3 receptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jul;346(1):69-75. PubMed PMID: 1383832.